Q Chip Ltd announces appointment of Tony Mills
Tony has over 20 years experience in intellectual property (IP) management and biotech commercialisation. After training as a virologist he worked in the vaccine industry for several years before joining the IP development company, BTG, where he licensed vaccine related IP worldwide. Tony was a key member of the team that founded Peptide Therapeutics, acquired as Acambis in 2008 by Sanofi Aventis for £280 million. More recently Tony has continued his interest in the commercialisation of biotech as VP Business Development at BioVex, followed by a role as an Executive Director of Phynova, the Oxford based company deriving novel drug candidates from plants.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.